SCHEMBL6435294

SCHEMBL6435294

N/N=C(\c1cccc(C(=O)O)c1)c1nc2nonc2nc1Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBS P35520 1/20 0.45
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
MAPT P10636 4/20 0.40
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
TP53 P04637 2/20 0.39
CCR2 P41597 1/20 0.39
CCR5 P51681 1/20 0.39
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
RHOA P61586 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
KDR P35968 1/20 0.37
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.36
WDR5 P61964 1/20 0.36
MYC P01106 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6435311 1.00 CBS (0.45) CBSMEN1KMT2AMAPTALDH1A1
SCHEMBL6415683 0.92 CSNK2A1 (0.45) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6415701 0.92 CSNK2A1 (0.45) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6412976 0.88 MAPT (0.40) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL6412964 0.88 MAPT (0.40) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL6415968 0.88 RHOA (0.47) MEN1KMT2AMAPTRHOAL3MBTL1
SCHEMBL6415954 0.88 RHOA (0.47) MEN1KMT2AMAPTRHOAL3MBTL1
SCHEMBL6419747 0.87 BIRC5 (0.43) CBSMEN1KMT2AMAPTALDH1A1
SCHEMBL6432179 0.83 MAPT (0.38) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL6432166 0.83 MAPT (0.38) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 CBS 4589/4885MEN1 4392/4885KMT2A 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.